BioSpace News Archive

Soligenix, Inc. announced publication of immunogenicity studies for RiVax® identifying novel correlates of immune protection to facilitate potential approval under the United States Food and Drug Administration “Animal Rule.” The article, titled “A Multivariate Model Combining Endpoint and Epitope-specific Antibody Responses as a Correlate of Protection to Ricin Toxin,” has been submitted to the peer-reviewed medical journal Vaccine and a preprint is available here.

Two additional abstracts featuring Milciclib in treating Hepatocellular Carcinoma to be published online

Study to enroll 144 patients with COVID-19-associated non-acute lung injury in an attempt to decrease progression to Acute Respiratory Distress Syndrome and need for ICU care

Orexo AB announces it has acquired the exclusive US rights to GAIA AG’s deprexis®, a digital therapy to help patients manage their symptoms of depression and one of the most researched digital therapies in the world.

Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® has been granted Breakthrough Therapy Designation in the U.S. for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.

Transparency Market Research has published a new report titled, ‘Drugs of Abuse Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

According to the report, the global retinal disorder treatment market was valued at ~US$ 9.2 Bn in 2018 and is projected to expand at a CAGR of ~8% from 2019 to 2027.

Duplex Sequencing is a commonly used technique to improve DNA sequencing accuracy.

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus infection, reports its first quarter 2020 financial results, provides a pipeline update and announces the establishment of a new research initiative focused on the identification of novel therapies to combat COVID-19.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the company’s management is scheduled to present at the 2020 Bank of America Securities Health Care Conference.